Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-
related glycemic excursions through augmentation of insulin and inhibition of glucagon …

Although the gastrointestinal (GI) tract possesses intrinsic neural plexuses that allow a
significant degree of autonomy over GI functions, the central nervous system (CNS) provides …

INTRODUCTION Transmembrane signaling of heterotrimeric guanine nucleotide–binding
protein (G protein)–coupled receptors (GPCRs) is mediated by ligand-dependent …

The cAMP-dependent protein kinase (PKA) system represents a primary cell-signaling
pathway throughout systems and across species. PKA facilitates the actions of hormones …

The incretin hormone glucagon-like peptide-1 (GLP-1) has received enormous attention
during the past three decades as a therapeutic target for the treatment of obesity and type 2 …

This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic …

Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the
intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene …

Abstract The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of
the key properties of over 2000 human drug targets with their pharmacology, plus links to an …